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Background
Iodinated contrast media (ICM) are diagnostic agents
used in millions of X-ray procedures yearly. Although
current agents are usually well tolerated, mild immediate
hypersensitivity reactions (IHR) occur in about 0.15% to
3% of administrations and severe IHRs in 0.01% to
0.04%. Despite this low incidence these reactions are an
important clinical problem because the increasingly
large amount of administrations per year worldwide.
New data indicate that many of the immediate reactions
are caused by an IgE-mediated activation of mast cells
in the organs affected.
Methods
A retrospective review of adverse reactions to ICM
between 2011 and 2012 in a tertiary hospital was carried
out. Allergy study was performed in all patients who
developed immediate hypersensitivity reactions. Skin
tests for contrast media (Iomeprol, Iobitridol, Iohexol,
Iodixanol, Amidotrizoato) were performed. We analysed
the characteristics of patients who had severe reactions
(Grade III-IV de Müller).
Results
73,962 radiological contrast studies were performed during
2011 and 2012. 80 (0.011%) patients showed immediate
hypersensitivity reactions to contrast media, 4 of them had
severe reactions to ICM. Three patients, 2 males and 1
female, ages ranging from 60 to 78 years, were studied in
Allergy unit. One patient had atopy. Two patients were on
antihypertensive treatment (beta-blockers, angiotensin II
receptor blockers, calcium channel blockers). All patients
had at least 1 previous study with iodinated contrast in the
past that had been well tolerated. Iomeprol was the
contrast media involved in all the patients, incidence of
0.008% (Poisson 95% CI: 0.004% to 0.015%), no fatality.
Skin tests (Skin Prick Test in one patient, and Intradermal
test on the other two) were positive for Iomeprol.
2/3 showed negativity for the other contrasts tested and
1/3 showed also a positive response to Iohexol. Both posi-
tives results were confirmed with basophil activation test.
Conclusion
Incidence of severe immediate reactions to iodinated
contrast media is very low. They are IgE mediated at
least in 75% of cases in our cohort. There was at least
one previous exposure to iodinated contrast before
developing the reaction.
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